Zheren Wang

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Osteosarcoma (OS) is the leading primary malignant bone tumor in children and young adults. It is response for a high mortality rate. Nowadays, few researches have been performed on sorafenib against OS and no tools are available to guide the use of sorafenib in the OS treatment. In this study, we aim to investigate the effect of sorafenib on OS cell MG63(More)
  • 1